Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)-Reference-Cited by-同舟云学术

Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)

Published:2020-05 Issue: Volume:143 Page:27-35
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Eide Inger Johanne Zwicky,Helland Åslaug,Ekman Simon,Mellemgaard Anders^ORCID,Hansen Karin Holmskov,Cicenas Saulius,Koivunen Jussi,Grønberg Bjørn Henning,Brustugun Odd Terje

Funder

AstraZeneca and the South-Eastern Norway Regional Health Authority

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference32 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018

2. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N. Engl. J. Med.,2004

3. EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery;Helland;J. Thorac. Oncol.,2011

4. The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population;Skov;APMIS,2015

5. Epidermal growth factor receptor mutations in 510 Finnish non--small-cell lung cancer patients;Maki-Nevala;J. Thorac. Oncol.,2014

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer;European Journal of Cancer;2024-09

2. Network-based elucidation of colon cancer drug resistance mechanisms by phosphoproteomic time-series analysis;Nature Communications;2024-05-09

3. Clinical efficacy and safety analysis of aumolertinib in real-world treatment of EGFR-mutated advanced non-small-cell lung cancer;Frontiers in Pharmacology;2024-04-09

4. Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and next-generation sequencing;Expert Review of Anticancer Therapy;2024-04-02

5. Combination of Osimertinib and Olaparib Therapy to Treat Non-Small Cell Lung Cancer and High-Grade Serous Ovarian Carcinoma: A Case Report;Current Oncology;2024-01-19